A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03292133 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 25, 2017
Last Update Posted : January 24, 2022
|
Sponsor:
Massachusetts General Hospital
Collaborator:
Novartis
Information provided by (Responsible Party):
Zofia Piotrowska, Massachusetts General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | October 31, 2022 |
| Estimated Study Completion Date : | October 31, 2025 |